Twigg SM, et al. - Using data from three multicenter, randomized, open-label, parallel-group, phase 3a studies of similar design, researchers conducted a post hoc patient-level meta-analysis to investigate the association of baseline patient characteristics with study outcomes in patients with type 2 diabetes receiving insulin glargine 300 U/mL (Gla-300) vs glargine 100 U/mL (Gla-100) over a 6-month period. Findings showed that, irrespective of patient age, body mass index, age at onset of diabetes, or duration of diabetes, comparable glycemic control was observed with Gla-300 vs Gla-100 with less hypoglycemia.